Topical Prostaglandin F2α Analog Induced Poliosis

In a case series from 2004, seven patients who were treated with topical prostaglandin F2α (PGF2α) analogs for primary open-angle glaucoma developed bilateral poliosis, which is the loss of pigment in eyelashes and/or eyebrows. This side effect occurred either alone or in combination with other adverse effects associated with PGF2α analog therapy. The study concluded that poliosis should be considered a possible adverse effect of topical PGF2α analog therapy, a connection that had not been reported prior to this study. Consequently, the use of topical PGF2α analogs should be considered when diagnosing patients with poliosis.